Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of pulmonary hypertension (PH) and heart failure (HF), announced the successful initiation and first two patients enrollment for its global multicenter clinical study exploring the percutaneous pulmonary artery denervation (PADN) treatment for pulmonary hypertension associated with left heart disease. This landmark event took place at Centro Hospitalar Universitário de Lisboa Central – Hospital de Santa Marta in Portugal, marking the beginning of Pulnovo Medical’s innovative product deployment on a global scale.
https://pharmabiz.com/NewsDetails.aspx?aid=170096&sid=2
Under the guidance of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, Prof. Ruben Ramos and his team successfully performed the PADN procedure on two patients. The procedure was smooth, the devices easy to operate, and the results were excellent.
The successful first enrollment in this clinical study not only explores medical technology innovation but also aims to further validate the effectiveness and safety of PADN technology, providing better medical services for patients and advancing the development of related disciplines.
Prof. Ruben Ramos said: “PADN technology shows great potential in treating pulmonary hypertension associated with left heart disease. We are delighted to be the first in Europe to participate in this global clinical study. Our team is confident in this project and looks forward to bringing more treatment options to European pulmonary hypertension patients through this study. PADN is not only a new treatment method but also brings new hope to patients suffering from pulmonary hypertension.
Revolutionary Products Shaping the Future of Cardiopulmonary Care
Pulnovo Medical’s flagship technologies are transforming the way physicians approach complex cardiopulmonary conditions. The company’s work is particularly notable in the areas of heart failure, pulmonary hypertension, and chronic obstructive pulmonary disease (COPD), as well as in the development of biomedical devices that enhance both diagnostics and treatment.
Another groundbreaking development is the implantable cardiac assist device (ICAD), which is designed to support patients suffering from severe heart failure. The ICAD represents a significant leap in heart failure management by offering a smaller, more efficient solution compared to traditional heart pumps. This device enhances heart function by providing mechanical support to the heart’s pumping action, reducing symptoms and improving patients’ quality of life.
Commitment to Research and Development
What sets Pulnovo Medical apart from other healthcare innovators is its unwavering commitment to research and development (R&D). The company allocates a significant portion of its resources to R&D, collaborating with leading medical universities, research institutions, and healthcare providers to stay at the forefront of cardiopulmonary care. This collaboration not only accelerates the development of new technologies but also ensures that the company’s products are backed by solid clinical evidence and meet the highest standards of medical practice.
Pulnovo Medical has also invested heavily in clinical trials to validate the safety and efficacy of its products, ensuring that every new technology is rigorously tested before it reaches patients. This commitment to scientific rigor has earned the company numerous accolades in the medical community and has helped it build strong relationships with physicians and healthcare organizations around the world.
A Global Vision for Health Innovation
While Pulnovo Medical has established itself as a leader in the Chinese healthcare market, the company is increasingly expanding its reach to international markets. With a growing presence in Europe, North America, and Southeast Asia, Pulnovo Medical is positioning itself as a global leader in the field of cardiopulmonary care. The company’s innovations have already caught the attention of healthcare providers in these regions, where there is a rising demand for more effective, patient-centric treatments for heart and lung diseases.
A Future of Transformative Impact
As Pulnovo Medical continues to push the boundaries of innovation in cardiopulmonary care, the company is laying the foundation for a future where heart and lung diseases can be managed more effectively, with greater precision and fewer complications. With its commitment to cutting-edge technology, research, and patient-centered care, Pulnovo Medical is not just leading the way in medical technology—it’s shaping the future of healthcare itself.
